Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
Latest Information Update: 03 Feb 2026
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sacituzumab Tirumotecan (Primary) ; Tagitanlimab (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms ST-A-TN
Most Recent Events
- 03 Feb 2026 New trial record